Ginkgo and AD: Key negatives and lessons from GuidAge

The Lancet Neurology

Volumn 11, Issue 10, 2012, Pages 836-837

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; APOLIPOPROTEIN E3; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE; PLACEBO;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; FOLLOW UP; HEALTH BEHAVIOR; HUMAN; LETTER; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MEMORY DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84866447872     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70212-0     Document Type: Letter

References (14)

1. DeFeudis FV, Drieu K Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets 2000, 1:25-58.
2. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000, 12:1882-1890.
3. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002, 99:12197-12202.
4. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y EGb761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J 2007, 21:2400-2408.
5. Vellas B, Coley N, Ousset P-J, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012, for the GuidAge Study Group, published online Sept 6. http://dx.doi.org/10.1016/S1474-4422(12)70206-5.
6. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.
7. Canter PH, Ernst E Ginkgo biloba is not a smart drug: an updated systematic review of randomised clinical trials testing the nootropic effects of G. biloba extracts in healthy people. Hum Psychopharmacol 2007, 22:265-278.
8. Birks J, Grimley Evans J Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009, 2. CD003120.
9. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005, 2:541-551.
10. McCarney R, Fisher P, Iliffe S, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2008, 23:1222-1230.
11. Andrieu S, Gillette S, Amouyal K, et al. Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003, 58:M372-M377.
12. Meinert CL, Breitner JCS Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2008, 4(suppl 1):S7-14.
13. Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E e{open}4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 2008, 12:2762-2771.
14. Richard E, Andrieu S, Solomon A, et al. Methodological challenges in designing dementia prevention trials-The European Dementia Prevention Initiative (EDPI). J Neurol Sci 2012, published online July 18. http://dx.doi.org/10.1016/j.jns.2012.06.012.